Italia markets open in 27 minutes

Castle Biosciences, Inc. (CSTL)

NasdaqGM - NasdaqGM Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
23,80-0,61 (-2,52%)
Alla chiusura: 04:00PM EDT
23,80 0,00 (0,00%)
Dopo ore: 04:01PM EDT

Castle Biosciences, Inc.

505 South Friendswood Drive
Suite 401
Friendswood, TX 77546
United States
866 788 9007
https://castlebiosciences.com

Settore/iHealthcare
SettoreDiagnostics & Research
Impiegati a tempo pieno638

Figure dirigenziali chiave

NomeTitoloRetribuzioneEsercitateAnno di nascita
Mr. Derek J. MaetzoldFounder, CEO, President & Director1,61MN/D1962
Mr. Frank StokesCFO & Treasurer880,25k75,52k1970
Ms. Kristen M. Oelschlager R.N.Chief Operating Officer828,48k234,2k1968
Mr. Tobin W. JuvenalChief Commercial Officer829,1k126,36k1960
Camilla ZuckeroVice President of Investor Relations & Corporate AffairsN/DN/DN/D
Ms. Alice Bahner IzzoSenior Vice President of MarketingN/DN/DN/D
Mr. Kevin DomanVice President of SalesN/DN/DN/D
Ms. Keli GreenbergVP of Human Resources & Executive Director of Human ResourcesN/DN/DN/D
Dr. Robert W. Cook Ph.D.Senior Vice President of Research & DevelopmentN/DN/D1972
Dr. Matthew Goldberg M.D.Senior Vice President of MedicalN/DN/DN/D
Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Castle Biosciences, Inc., a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus. In addition, the company provides DecisionDx-UM test, a proprietary risk stratification GEP test that predicts the risk of metastasis for patients with uveal melanoma; and IDgenetix, a pharmacogenomic test that helps guide drug treatment for major depressive disorder, schizophrenia, bipolar disorder, anxiety disorders, social phobia, obsessive-compulsive personality disorder, post-traumatic stress disorder, and attention deficit hyperactivity disorder. It offers its products to skin cancer, gastroenterology, and mental health markets. The company was incorporated in 2007 and is headquartered in Friendswood, Texas.

Governance aziendale

L'ISS Governance QualityScore di Castle Biosciences, Inc. al 1 maggio 2024 è 9. I criteri di valutazione fondamentali sono revisione: 4; Consiglio di Amministrazione: 6; diritti degli azionisti: 8; retribuzione: 10.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.